Trace Impurity Analysis for Risk Reduction in Medical Device Development

Why Trace Impurities Matter Early in Development

Trace impurities are still too often treated as a late-stage requirement tied to regulatory submission. In medical device development, they are more accurately an early signal of how materials and processes will perform under real conditions.

These impurities are small, unintended chemical substances that remain in a material or component after manufacturing, processing, or sterilization. They are typically present at very low concentrations, often in the ppb to ppt range. 

For medical device developers working with polymers, biologics, or tissue-derived systems, these compounds are not just analytical artifacts. They can influence biological response, affect material stability, and introduce variability that surfaces during verification and validation.

When impurity profiles are not fully understood early, risk is often discovered downstream when changes are more difficult to implement and timelines are less flexible. In many cases, the issues emerge during biocompatibility or extractables and leachables evaluations, where expectations for chemical characterization are increasingly well defined (ISO 10993‑18/FDA), resulting in delayed submissions or costly reformulation efforts.

Limits of Conventional Analytical Approaches

Many of the challenges associated with trace impurities are not new. What has changed is the level of sensitivity and selectivity required to fully characterize them.

In complex matrices, several issues consistently appear when using established quantitative workflows:

• Low-abundance compounds are masked by matrix interference
• Co-eluting species suppress or distort signals
• Structurally similar compounds are difficult to resolve
• Unknown impurities go undetected when relying solely on targeted methods
• Results from suboptimal methods are variable, limiting confidence in conclusions

These limitations create gaps in visibility. Teams may move forward with incomplete data, assuming risk has been addressed when key impurities remain undetected.

Analytical Capability as a Driver of Better Decisions

Recent improvements in LC-MS have changed how trace impurities can be evaluated during development.

High-resolution mass spectrometry, when combined with low-flow chromatography and ion mobility separation, provides a more complete view of impurity profiles. These systems support:

• Detection of compounds at ultra-trace levels
• Separation of analytes from complex biological or polymer backgrounds
• Resolution of closely related chemical species
• Untargeted full‑scan acquisition for early profiling of unknowns
• Consistent performance across repeated analyses

Working in the pg/mL to ng/mL range for optimized targeted methods, these capabilities allow teams to connect impurity data to specific materials and process steps. 

The result is not just improved detection and identification, but clearer insight into cause and effect. 

Addressing Common Challenges in Trace Impurity Analysis

These capabilities are most valuable when considered in the context of the specific analytical challenges they are intended to solve.

In practice, trace impurity analysis often breaks down at the edges of detection and separation. Low-level compounds can be lost in matrix interference, unknown species may go undetected in targeted methods, and co-eluting or structurally similar compounds can limit confidence in results. 

Advances in LC-MS workflows improve performance in these specific areas. Increased sensitivity enables detection of compounds that would otherwise remain below the noise threshold. High-resolution and accurate mass measurements allow differentiation of closely related species, while ion mobility adds an orthogonal separation dimension that reduces spectral congestion and improves confidence in identifying unknowns. 

At the same time, improvements in instrument stability and method robustness support reproducible datasets across runs. This is particularly important when tracking changes across process iterations or comparing results between studies.

Together, these capabilities help close the gap between what is present in a sample and what can be reliably detected, resolved, and interpreted.

Process Optimization in Polymer-Based Devices

Polymer devices often contain residuals from processing aids, monomers, or cleaning steps. When these include cytotoxic compounds, developers need to understand how process changes influence impurity levels.

In one case, a manufacturer required precise quantification across multiple process iterations. The goal was to measure small changes as cleaning and manufacturing conditions were adjusted.

A targeted LC-MS method enabled:

• Reliable measurement at very low concentrations
• Tracking of incremental changes across iterations
• Direct comparison between process conditions

This dataset allowed the team to refine their approach with confidence and reduce impurity levels in a controlled way. The same data can also support future regulatory discussions.

Selective Quantitation in Tissue-Derived Systems

Tissue-derived devices present a different type of complexity. Residual antibiotics from processing must often be measured at low levels, but the biological matrix can interfere with quantitation.

In this scenario, analytical performance depends on selectivity as much as sensitivity.

Using LC-MS methods optimized for complex matrices:

• Target compounds were separated from endogenous components
• Multiple analytes were measured within a single run
• Detection limits aligned with safety expectations

This approach provided a reliable method that could support continued development and regulatory alignment. 

Where Trace Impurity Analysis Adds Value

The role of trace impurity analysis is changing. It is no longer only a confirmation step before submission.

Instead, it can function as a continuous input into development decisions. This shift allows teams to:

• Understand how impurity profiles evolve over time
• Evaluate the impact of process changes with greater precision
• Build datasets that support both internal decisions and regulatory expectations

This approach improves both efficiency and confidence as programs advance.

How iFyber Supports Trace Impurity Analysis

Advanced instrumentation is only one part of effective impurity analysis. The ability to design methods, prepare samples appropriately, and interpret results in context is equally important.

iFyber applies LC-MS workflows that are tailored to complex medical device materials and biological systems. This includes:

• Targeted and untargeted impurity analysis
• Method development aligned with specific matrices and compounds
• Support for interpreting results in relation to materials and processes

The focus is on generating data that can be used to guide development decisions, not just report results.

Turning Insight into Action

Trace impurities provide a window into how materials, processes, and devices perform under real-world conditions. When evaluated early and with the right level of sensitivity, they can highlight risks that would otherwise surface later in development.

Advances in LC-MS now allow teams to detect, identify, and quantify these compounds with greater clarity and consistency. This makes it possible to move from reactive testing to a more proactive, data-driven approach to development.

For medical device developers, the opportunity is to use impurity data not just for compliance, but to guide decisions that improve performance, reduce rework, and support regulatory readiness.

If you are evaluating impurity risks in polymer or tissue-derived systems, we can help design a targeted or untargeted LC-MS strategy tailored to your materials and regulatory goals.

Connect with the iFyber team to discuss your application, analytical challenges, and how tailored LC-MS workflows can support your development and regulatory objectives.